Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

A. Bergamo; C. Gaiddon; J.H.M. Schellens; J.H. Beijnen; G. Sava

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

A. Bergamo
, C. Gaiddon
, J.H.M. Schellens
, J.H. Beijnen
, G. Sava

extern

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with some success the clinical evaluations of phase I and preliminary phase II trials in patients. Here we highlight the strategies that have led to the discovery of metal-based (NAMI-A and KP1019) and of organometallic (RM175, RAPTA-T, RDC11 and DW1/2) ruthenium-based complexes, and we report their main biological/pharmacological characteristics and expectations for further development.

Original language	Undefined/Unknown
Pages (from-to)	90-9
Number of pages	10
Journal	Journal of Inorganic Biochemistry
Volume	106
Issue number	1
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{2142003ce0554e7dbee6ab1f7372582e,

title = "Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.",

abstract = "The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with some success the clinical evaluations of phase I and preliminary phase II trials in patients. Here we highlight the strategies that have led to the discovery of metal-based (NAMI-A and KP1019) and of organometallic (RM175, RAPTA-T, RDC11 and DW1/2) ruthenium-based complexes, and we report their main biological/pharmacological characteristics and expectations for further development.",

author = "A. Bergamo and C. Gaiddon and J.H.M. Schellens and J.H. Beijnen and G. Sava",

year = "2012",

language = "Undefined/Unknown",

volume = "106",

pages = "90--9",

journal = "Journal of Inorganic Biochemistry",

issn = "0162-0134",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

AU - Bergamo, A.

AU - Gaiddon, C.

AU - Schellens, J.H.M.

AU - Beijnen, J.H.

AU - Sava, G.

PY - 2012

Y1 - 2012

N2 - The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with some success the clinical evaluations of phase I and preliminary phase II trials in patients. Here we highlight the strategies that have led to the discovery of metal-based (NAMI-A and KP1019) and of organometallic (RM175, RAPTA-T, RDC11 and DW1/2) ruthenium-based complexes, and we report their main biological/pharmacological characteristics and expectations for further development.

AB - The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with some success the clinical evaluations of phase I and preliminary phase II trials in patients. Here we highlight the strategies that have led to the discovery of metal-based (NAMI-A and KP1019) and of organometallic (RM175, RAPTA-T, RDC11 and DW1/2) ruthenium-based complexes, and we report their main biological/pharmacological characteristics and expectations for further development.

M3 - Article

SN - 0162-0134

VL - 106

SP - 90

EP - 99

JO - Journal of Inorganic Biochemistry

JF - Journal of Inorganic Biochemistry

IS - 1

ER -